Physician profile
Norma Perez
NPI 1356573653
$1,287.76
in general payments reported to CMS, 2019-2025
13 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Pediatric Infectious Diseases provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $22.56 · 2021: $186 · 2022: $38.53 · 2023: $47.31 · 2024: $209 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $158.76 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $156.39 | 2019 | |
| Amgen INC. | $149.71 | 2021-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $92.47 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $74.13 | 2019 | |
| Abbott Laboratories | $21.03 | 2025 | Jot Dx |
| Melinta Therapeutics, LLC | $15.90 | 2019 | |
| Pfizer INC. | $15.77 | 2019 | |
| Allergan, INC. | $14.49 | 2019 | |
| Ibsa Pharma INC. | $11.91 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.